{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:39:07Z","timestamp":1760747947506,"version":"build-2065373602"},"reference-count":52,"publisher":"BMJ","issue":"7","funder":[{"name":"Eve Appeal","award":["EVE\/0027"],"award-info":[{"award-number":["EVE\/0027"]}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","award":["EMSG1L7R"],"award-info":[{"award-number":["EMSG1L7R"]}],"id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust\/Institute of Cancer Research","doi-asserted-by":"publisher","award":["NIHR203314"],"award-info":[{"award-number":["NIHR203314"]}],"id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015652","name":"Barts Charity","doi-asserted-by":"publisher","award":["EMSG1M9R"],"award-info":[{"award-number":["EMSG1M9R"]}],"id":[{"id":"10.13039\/100015652","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2024,3,9]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>1 in 40 UK Jewish individuals carry a pathogenic variant in <jats:italic>BRCA1\/BRCA2<\/jats:italic>. Traditional testing criteria miss half of carriers, and so population genetic testing is being piloted for Jewish people in England. There has been no qualitative research into the factors influencing <jats:italic>BRCA<\/jats:italic> awareness and testing experience in this group. This study aimed to explore these and inform improvements for the implementation of population genetic testing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Qualitative study of UK Jewish adults who have undergone <jats:italic>BRCA<\/jats:italic> testing. We conducted one-to-one semistructured interviews via telephone or video call using a predefined topic guide, until sufficient information power was reached. Interviews were audio-recorded, transcribed verbatim and interpreted using applied thematic analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>32 individuals were interviewed (28 carriers, 4 non-carriers). We interpreted five themes intersecting across six time points of the testing pathway: (1) individual differences regarding personal\/family history of cancer, demographics and personal attitudes\/approach; (2) healthcare professionals\u2019 support; (3) pathway access and integration; (4) nature of family\/partner relationships; and (5) Jewish community factors. Testing was largely triggered by connecting information to a personal\/family history of cancer. No participants reported decision regret, although there was huge variation in satisfaction. Suggestions were given around increasing UK Jewish community awareness, making information and support services personally relevant and proactive case management of carriers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>There is a need to improve UK Jewish community <jats:italic>BRCA<\/jats:italic> awareness and to highlight personal relevance of testing for individuals without a personal\/family history of cancer. Traditional testing criteria caused multiple issues regarding test access and experience. Carriers want information and support services tailored to their individual circumstances.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jmg-2023-109576","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T13:20:18Z","timestamp":1712236818000},"page":"716-725","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["<i>BRCA<\/i> awareness and testing experience in the UK Jewish population: a qualitative study"],"prefix":"10.1136","volume":"61","author":[{"given":"Katrina","family":"Sarig","sequence":"first","affiliation":[{"name":"Queen Mary University of London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1967-813X","authenticated-orcid":false,"given":"Samuel","family":"Oxley","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, UK"},{"name":"Department of Gynaecological Oncology, Barts Health NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwin","family":"Kalra","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, UK"},{"name":"Department of Gynaecological Oncology, Barts Health NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Sobocan","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, UK"},{"name":"University of Maribor, Maribor, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin T","family":"Fierheller","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michail","family":"Sideris","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, UK"},{"name":"Department of Gynaecological Oncology, Barts Health NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Gootzen","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Ferris","sequence":"additional","affiliation":[{"name":"Lane End Medical Practice, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalind A","family":"Eeles","sequence":"additional","affiliation":[{"name":"Oncogenetics, Institute of Cancer Research, Sutton, UK"},{"name":"Royal Marsden NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8482-5784","authenticated-orcid":false,"given":"D Gareth","family":"Evans","sequence":"additional","affiliation":[{"name":"Manchester Centre for Genomic Medicine, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha L","family":"Quaife","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3381-5057","authenticated-orcid":false,"given":"Ranjit","family":"Manchanda","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, UK"},{"name":"Department of Gynaecological Oncology, Barts Health NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"2025101715305367000_61.7.716.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7112"},{"key":"2025101715305367000_61.7.716.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02112"},{"key":"2025101715305367000_61.7.716.3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1415979111"},{"key":"2025101715305367000_61.7.716.4","doi-asserted-by":"publisher","DOI":"10.1002\/gepi.1022"},{"key":"2025101715305367000_61.7.716.5","unstructured":"NICE . Familial breast cancer: full guideline. 2017."},{"key":"2025101715305367000_61.7.716.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.188"},{"key":"2025101715305367000_61.7.716.7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33378"},{"key":"2025101715305367000_61.7.716.8","first-page":"e16","article-title":"Risk-reducing salpingo-oophorectomy and the use of hormone replacement therapy below the age of natural menopause: scientific impact paper No.66 October 2021: scientific impact paper No.66","volume":"129","author":"Manchanda","year":"2022","journal-title":"BJOG"},{"key":"2025101715305367000_61.7.716.9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.2140","article-title":"Exome sequencing\u2013based screening for Brca1\/2 expected pathogenic variants among adult biobank participants","volume":"1","author":"Manickam","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2025101715305367000_61.7.716.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-018-0277-0"},{"key":"2025101715305367000_61.7.716.11","doi-asserted-by":"publisher","DOI":"10.1038\/ng1096-185"},{"key":"2025101715305367000_61.7.716.12","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.15905"},{"key":"2025101715305367000_61.7.716.13","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/7.5.801"},{"key":"2025101715305367000_61.7.716.14","doi-asserted-by":"publisher","DOI":"10.1086\/302853"},{"key":"2025101715305367000_61.7.716.15","doi-asserted-by":"publisher","DOI":"10.1126\/science.1088759"},{"key":"2025101715305367000_61.7.716.16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174344","article-title":"Implementation of multigene germline and parallel somatic genetic testing in epithelial ovarian cancer: SIGNPOST study","volume":"13","author":"Chandrasekaran","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025101715305367000_61.7.716.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913948"},{"key":"2025101715305367000_61.7.716.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005936"},{"key":"2025101715305367000_61.7.716.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-018-0406-9"},{"key":"2025101715305367000_61.7.716.20","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2012-101415"},{"key":"2025101715305367000_61.7.716.21","unstructured":"England N . Clinical commissiong policy: BRCA testing for BRCA mutations in breast and ovarian cancer, 2015. Available: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2018\/07\/Genetic-testing-for-BRCA1-and-BRCA2-mutations.pdf"},{"key":"2025101715305367000_61.7.716.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.04.023"},{"key":"2025101715305367000_61.7.716.23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.6314"},{"key":"2025101715305367000_61.7.716.24","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2017-105195"},{"key":"2025101715305367000_61.7.716.25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/1471-0528.17283","article-title":"Population-based genetic testing for cancer susceptibility genes: quo Vadis","volume":"130","author":"Manchanda","year":"2023","journal-title":"BJOG"},{"key":"2025101715305367000_61.7.716.26","doi-asserted-by":"crossref","unstructured":"Manchanda R , Legood R , Burnell M , et al . Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history\u2013based testing. JNCI 2015;107. doi:10.1093\/jnci\/dju380","DOI":"10.1093\/jnci\/dju380"},{"key":"2025101715305367000_61.7.716.27","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ajog.2017.06.038","article-title":"Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry","volume":"217","author":"Manchanda","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"2025101715305367000_61.7.716.28","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-022-00571-9"},{"key":"2025101715305367000_61.7.716.29","unstructured":"Chronicle TJ . NHS to launch expanded BRCA genetic testing for Jewish community, 2022. Available: https:\/\/www.thejc.com\/news\/community\/nhs-to-launch-expanded-brca-genetic-testing-for-jewish-community-4zzTYVL49LNNUj3BQT9RRy"},{"key":"2025101715305367000_61.7.716.30","unstructured":"England N . The Jewish community\u2019s NHS BRCA screening programme, 2023. Available: https:\/\/jewishbrca.org"},{"key":"2025101715305367000_61.7.716.31","doi-asserted-by":"publisher","DOI":"10.1177\/1049732315617444"},{"key":"2025101715305367000_61.7.716.32","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/1471-0528.15654","article-title":"Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study","volume":"126","author":"Manchanda","year":"2019","journal-title":"BJOG"},{"key":"2025101715305367000_61.7.716.33","doi-asserted-by":"publisher","DOI":"10.1037\/0278-6133.7.4.355"},{"key":"2025101715305367000_61.7.716.34","doi-asserted-by":"crossref","unstructured":"Manchanda R , Loggenberg K , Sanderson S , et al . Population testing for cancer predisposing Brca1\/Brca2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. J Natl Cancer Inst 2015;107. doi:10.1093\/jnci\/dju379","DOI":"10.1093\/jnci\/dju379"},{"key":"2025101715305367000_61.7.716.35","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.182"},{"key":"2025101715305367000_61.7.716.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2010.01499.x"},{"key":"2025101715305367000_61.7.716.37","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/1471-0528.16994","article-title":"Jewish cultural and religious factors and uptake of population based BRCA testing across denominations: a cohort study","volume":"129","author":"Reisel","year":"2022","journal-title":"BJOG"},{"key":"2025101715305367000_61.7.716.38","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s10897-018-0276-y","article-title":"I am uncertain about what my uncertainty even is\u201d: men\u2019s uncertainty and information management of their BRCA-related cancer risks","volume":"27","author":"Rauscher","year":"2018","journal-title":"J Genet Couns"},{"key":"2025101715305367000_61.7.716.39","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/gim.2016.175","article-title":"Population screening for Brca1\/Brca2 mutations: lessons from qualitative analysis of the screening experience","volume":"19","author":"Lieberman","year":"2017","journal-title":"Genet Med"},{"key":"2025101715305367000_61.7.716.40","unstructured":"Statistics OfN . Religion, England and Wales: census. 2021. Available: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/culturalidentity\/religion\/bulletins\/religionenglandandwales\/census2021"},{"key":"2025101715305367000_61.7.716.41","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2011.146"},{"key":"2025101715305367000_61.7.716.42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s10897-015-9845-5","article-title":"Experiences of women who underwent predictive BRCA 1\/2 Mutation testing before the age of 30","volume":"25","author":"Brunstrom","year":"2016","journal-title":"J Genet Couns"},{"key":"2025101715305367000_61.7.716.43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087696","article-title":"In their own words: treating very young Brca1\/2 mutation-positive women with care and caution","volume":"9","author":"Hoskins","year":"2014","journal-title":"PLoS One"},{"key":"2025101715305367000_61.7.716.44","doi-asserted-by":"publisher","DOI":"10.1007\/s10897-009-9232-1"},{"key":"2025101715305367000_61.7.716.45","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.pec.2020.12.019","article-title":"Sharing genetic test results with family members of BRCA, Palb2, Chek2, and ATM carriers","volume":"104","author":"Dean","year":"2021","journal-title":"Patient Educ Couns"},{"key":"2025101715305367000_61.7.716.46","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10897-012-9549-z","article-title":"Talking to children about maternal Brca1\/2 genetic test results: a qualitative study of parental perceptions and advice","volume":"22","author":"Farkas Patenaude","year":"2013","journal-title":"J Genet Couns"},{"key":"2025101715305367000_61.7.716.47","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ajog.2023.03.045","article-title":"Quality of life after risk-reducing surgery for breast and ovarian cancer prevention: a systematic review and meta-analysis","volume":"229","author":"Wei","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"2025101715305367000_61.7.716.48","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/1471-0528.16424","article-title":"Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study","volume":"128","author":"Gaba","year":"2021","journal-title":"BJOG"},{"key":"2025101715305367000_61.7.716.49","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10549-020-05949-z","article-title":"Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic Brca1 and Brca2 mutation carriers","volume":"185","author":"Galmor","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2025101715305367000_61.7.716.50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178392","article-title":"Qualitative analysis of how patients decide that they want risk-reducing mastectomy, and the implications for Surgeons in responding to emotionally-motivated patient requests","volume":"12","author":"Brown","year":"2017","journal-title":"PLoS One"},{"key":"2025101715305367000_61.7.716.51","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2020-107501"},{"key":"2025101715305367000_61.7.716.52","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12051028","article-title":"Unselected population genetic testing for personalised ovarian cancer risk prediction: a qualitative study using semi-structured interviews","volume":"12","author":"Gaba","year":"2022","journal-title":"Diagnostics (Basel)"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmg-2023-109576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T22:31:01Z","timestamp":1760740261000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmg-2023-109576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":52,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,6,20]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/jmg-2023-109576"],"URL":"https:\/\/doi.org\/10.1136\/jmg-2023-109576","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"type":"print","value":"0022-2593"},{"type":"electronic","value":"1468-6244"}],"subject":[],"published":{"date-parts":[[2024,4,4]]}}}